uBiome Appoints Dr. Catherine Lozupone, PhD, Respected Microbiologist, to its Scientific Advisory Board
“Moving the microbiome into personalized medicine is an exciting frontier, and I am happy to lend my expertise to further this endeavor.” - Dr. Lozupone, PhD
SAN FRANCISCO (PRWEB) November 07, 2018
uBiome, the leader in microbial genomics, announces the addition of Dr. Catherine Lozupone, PhD, faculty of the Computational Biosciences Program within the Department of Medicine, University of Colorado, Denver, to its Scientific Advisory Board. Joining the board of leading scientists and doctors from around the world, Dr. Lozupone will bring to uBiome an expertise on the factors that shape human microbiota composition in health and disease, particularly in the gastrointestinal tract. The appointment will help uBiome continue its advancement in human microbiome research.
“Through her extensive career, Dr. Lozupone has advanced clinical implications of the human microbiome and our understanding of health and disease,” Dr. Jessica Richman, PhD, co-founder and CEO of uBiome, said. “Her research background will be an immense asset to uBiome, and we are fortunate to have her as a member of the uBiome Scientific Advisory Board.”
In addition to her post with the Computational Biosciences Program, Dr. Lozupone is also an Associate Professor of Biomedical Informatics and Personalized Medicine at the Department of Medicine, University of Colorado, Denver. Her ongoing projects explore mechanistic relationships between the human microbiota and chronic inflammation and metabolic and lung co-morbidity in individuals infected with HIV, interactions between gut microbiota and the human immune system, and novel bioinformatics tools for multi-omic data analysis. Dr. Lozupone pursued her PhD in Molecular, Cellular, and Developmental Biology at the University of Colorado, Boulder. She has authored over 50 scientific publications and currently serves as a Editor in Chief of npj Biofilms and Microbiomes, as Associate Editor of mSystems, and as a peer reviewer for respected journals including Nature, Nature Microbiology, Cell Host and Microbe, BMC Microbiology, FEMS Microbiology Ecology, International Microbiology, Journal of Pediatric Gastroenterology and Nutrition, Molecular Ecology, PLoS One, PLoS Pathogens, and more.
About joining uBiome's Scientific Advisory Board, Dr. Lozupone said, “Moving the microbiome into personalized medicine is an exciting frontier, and I am happy to lend my expertise to further this endeavor.”
In addition to Dr. Lozupone, the uBiome Scientific Advisory Board also includes Dr. Joseph DeRisi (MacArthur Genius and UCSF professor), Dr. Atul Butte (head of the Institute for Computational Health Sciences at UCSF), Dr. Katherine Pollard (Director, Gladstone Institute for Data Science and Biotechnology), Dr. Joel Palefsky (UCSF School of Medicine professor), Dr. George Church (leading geneticist at Harvard University), Dr. Liz Lipski (Academic Director of Nutrition and Integrative Health Programs at Maryland University of Integrative Health), Dr. Elaine Hsiao, PhD (UCLA), and other leading scientists. The company’s Medical Advisory Board includes Dr. Alan Green (Society for Participatory Medicine), Dr. Leo Treyzon (Cedars-Sinai Medical Center), Dr. Cynthia Geyer (Medical Director of Canyon Ranch, Lenox), Dr. Robynne Chutkan (Georgetown University Hospital), Michael Docktor (Boston Children’s Hospital), Dr. Tiffany Lester (Medical Director of Parsley Health in San Francisco), Dr. Joel Kahn (Founder of of the Kahn Center for Cardiac Longevity), as well as other accomplished clinicians.
Founded in 2012, uBiome is the leader in microbial genomics. The Company’s mission is to advance the science of the microbiome and make it useful to people. uBiome combines its patented proprietary precision sequencing™ with machine learning and artificial intelligence to develop wellness products, clinical tests, and therapeutic targets. uBiome has filed for over 250 patents on its technology, which includes sample preparation, computational analysis, molecular techniques, as well as diagnostic and therapeutic applications.
uBiome’s commercial products include SmartGut™, the world’s first sequencing-based clinical microbiome test, which identifies microbes in the gut for patients with chronic gut conditions such as IBD, IBS, Crohn’s Disease, and ulcerative colitis; SmartJane™, the first sequencing-based women’s health screening test, which genotypes all 19 clinically relevant strains of HPV, identifies four common STDs, and surveys more than 20 vaginal microbes associated with bacterial vaginosis and other conditions; and Explorer™, a health and wellness product to understand the role that food and lifestyle can play in wellness.
uBiome’s platform has been used by hundreds of thousands of consumers, patients, and doctors and more than 200 research institutions around the world, including the US Centers for Disease Control (CDC), US National Institutes of Health (NIH), Harvard University, Stanford University, the Massachusetts Institute of Technology (MIT), University of California, San Francisco, Oxford University, and the University of Sydney.
Since its launch, the company has received widespread recognition including CNN 10: Startups to Watch, the IVY Technology Award, CNN Future 30, and was named one of Fast Company’s Most Innovative Companies in Healthcare in 2016 and in Data Science in 2018, as well as a Technology Pioneer from the World Economic Forum in 2018. For more information, visit http://www.uBiome.com.